Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–18 of 18 results
Advanced filters: Author: "J. Morris" Clear advanced filters

  • The role of peatlands in future climate change is uncertain because peat-derived greenhouse gas emissions are difficult to predict. Now research shows that reduced methane emissions from drying peatlands are likely to be outweighed by increasing CO2 emissions.

    • Paul J. Morris
    News & Views
    Nature Climate Change
    Volume: 11, P: 561-562

  • What underlies the synthetic lethality between BRCA1/2 or 53BP1 loss and Polθ loss is unclear. Here, the authors show that RPA-RAD52-MRE11 drive lethality when Polθ is absent in these cells. In BRCA1/2-deficient cells, sensitivity to Polθ inhibition additionally depends on the inhibited protein.

    • George E. Ronson
    • Katarzyna Starowicz
    • Joanna R. Morris
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-16

  • BRCA1–BARD1 has a role in replication fork protection that is mediated by a mechanism of phosphorylation-targeted isomerization of BRCA1 and is independent of the canonical interaction between BRCA1 and PALB2.

    • Manuel Daza-Martin
    • Katarzyna Starowicz
    • Joanna R. Morris
    Research
    Nature
    Volume: 571, P: 521-527

  • BRCA1 ligase activity is tightly regulated to maintain genome stability and confer DNA double strand repair. Here the authors identify USP48 as a H2A deubiquitinating enzyme that acts as a BRCA1 E3 ligase antagonist and characterize its role during DNA repair.

    • Michael Uckelmann
    • Ruth M. Densham
    • Joanna R. Morris
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-16

  • To improve treatments for patients with castration-resistant prostate cancer, new biomarkers and surrogate end points for clinical trials are required. Identifying biomarkers that reflect clinical benefit and that guide personalized treatment plans are of the highest priority. This Review article outlines the framework for developing such biomarkers, including analytical validation, clinical validation and regulatory approval, and describes promising emerging biomarkers.

    • Howard I. Scher
    • Michael J. Morris
    • Glenn Heller
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 225-234

  • The E3 ubiquitin ligase activity of the BRCA1–BARD1 complex is required to reposition 53BP1 on damaged chromatin and to promote DNA resection and repair via homologous recombination, in a mechanism involving the chromatin remodeler SMARCAD1.

    • Ruth M Densham
    • Alexander J Garvin
    • Joanna R Morris
    Research
    Nature Structural & Molecular Biology
    Volume: 23, P: 647-655

  • Emerging findings provide compelling evidence that the BRCA1-binding partner BARD1 contributes yet further to BRCA1 function. BARD1 is crucial for positioning the E2 ubiquitin-conjugating enzyme that confers specificity of its ligase to residues on histone H2A, and BARD1 also promotes DNA damage–induced chromatin recruitment through an interaction with ubiquitin-conjugated Lys13 or Lys15 of H2A on the nucleosome core particle.

    • Joanna R. Morris
    News & Views
    Nature Structural & Molecular Biology
    Volume: 28, P: 708-710

  • Post-therapy prostate-specific antigen (PSA) changes have been associated with improved survival in castrate metastatic patients, but currently no drug has been approved strictly on the basis of a post-treatment decline in PSA, as it is unproven that such PSA changes are surrogates for true clinical benefits. Fleming and coauthors address the critical question of whether PSA post-therapy decline reflects true clinical benefit, and if it should be used as an intermediate endpoint for accelerated approval. The authors emphasize the importance of recognizing that there are a range of clinical benefits to patients that can favorably improve the quality and possibly the duration of survival independent of PSA.

    • Mark T Fleming
    • Michael J Morris
    • Howard I Scher
    Reviews
    Nature Clinical Practice Oncology
    Volume: 3, P: 658-667

  • The roles of melanocortins extend well beyond the regulation of energy homeostasis. In this article, the authors review their involvement in different pathophysiological states, which could lead to the development of improved therapeutics for pain and mood disorders, and cognitive impairments.

    • Vanni Caruso
    • Malin C. Lagerström
    • Helgi B. Schiöth
    Reviews
    Nature Reviews Neuroscience
    Volume: 15, P: 98-110